Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological intervention with platelet phospholipase A2.

R Nosal1, V Jancinova

  • 1Department of Cellular Pharmacology, Institute of Experimental Pharmacology, Slovak Academy of Sciences, Dubravska 9, SK-842 16 Bratislava 4, Slovakia.

Bratislavske Lekarske Listy
|January 23, 2002
PubMed
Summary

Cationic amphiphilic drugs inhibit platelet aggregation by interfering with arachidonic acid release, suggesting a new antiplatelet mechanism. This study explored drug effects on platelet phospholipase A2 (cPLA2) activation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the pharmacology of oxidative burst of human neutrophils.

Physiological research·2015
Same author

The effects of chloroquine and hydroxychloroquine on nitric oxide production in RAW 264.7 and bone marrow-derived macrophages.

Folia biologica·2014
Same author

Blood platelets and chloroquine.

Platelets·2010
Same author

Antiaggregatory Properties of Beta-adrenoceptor Blocking Drugs are Related to their Physico-chemical Properties.

Platelets·2010
Same author

The H(1)-histamine antagonist dithiaden inhibits human platelet function in vitro.

Platelets·2010
Same author

Carvedilol and adrenergic agonists suppress the lipopolysaccharide-induced NO production in RAW 264.7 macrophages via the adrenergic receptors.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2009

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Arachidonic acid metabolites are key regulators of platelet function, involved in adhesion and aggregation.
  • Pharmacological targeting of the arachidonate cascade is crucial for managing hyperactive platelets and preventing thromboembolic events.

Purpose of the Study:

  • To investigate and compare the effects of various cationic amphiphilic drugs (CADs) on platelet phospholipase A2 (cPLA2) activation.
  • To elucidate the role of cPLA2 inhibition as a potential antiplatelet mechanism.

Main Methods:

  • Human and rat platelets were isolated via differential centrifugation.
  • Platelet aggregation was measured using a dual-channel aggregometer.
  • Cytosolic phospholipase A2 (cPLA2) activity was quantified by measuring the release of radiolabeled arachidonic acid from phospholipids.

Related Experiment Videos

Main Results:

  • Beta-adrenoceptor blocking drugs (e.g., propranolol) and H1-histamine antagonists (e.g., dithiaden) demonstrated dose-dependent inhibition of platelet aggregation and arachidonic acid release.
  • The rank order of potency for inhibiting cPLA2 activity varied among drug classes but consistently showed antiplatelet effects.
  • Inhibition occurred regardless of whether platelet stimulation was receptor-mediated (thrombin) or bypassed receptors (Ca2+ ionophore).

Conclusions:

  • The investigated drugs exhibit non-specific inhibition of platelet cytosolic phospholipase A2 (cPLA2) at the intracellular level.
  • Drug interaction with cPLA2 represents an additional antiplatelet mechanism, complementing known effects on cyclooxygenase pathways and receptors.
  • These findings highlight cPLA2 as a potential therapeutic target for antiplatelet therapy.